SNDX
Syndax Pharmaceuticals, Inc.
$21.49
+4.63%
2026-05-08
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-119.07
EPS (TTM)
$-2.79
ROE
-189.5%
Revenue Growth (YoY)
223.6%
Profit Margin
-112.0%
Debt/Equity
829.75
Price/Book
27.77
Beta
0.41
Market Cap
$1.82B
Avg Volume (10D)
2.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$25.59
60D Low
$19.00
Avg Volume
1.5M
Latest Close
$21.49
Get breakout alerts for SNDX
Sign up for Breakout Scanner to receive daily notifications when SNDX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Syndax Pharmaceuticals, Inc. (SNDX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SNDX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SNDX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.